Vcanbio Cell & Gene Engineering Corp

Vcanbio Cell & Gene Engineering Corp Operating Cash Flow

The Operating Cash Flow of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Oct 16, 2026 is 313.63 M CNY. In the previous year, Operating Cash Flow was 285.19 M CNY — a change of 9.97% (higher).

Operating Cash Flow

313.63 MCNY

YoY

9.97%

Last updated:

Operating Cash Flow of Vcanbio Cell & Gene Engineering Corp is 2025 313.63 M CNY. Operating Cash Flow of Vcanbio Cell & Gene Engineering Corp was 2024 285.19 M CNY. It decreases by 9.97% higher compared to the previous year.

The Vcanbio Cell & Gene Engineering Corp Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
130.08 M CNY
Jan 1, 2019
241.49 M CNY
Jan 1, 2020
244.35 M CNY
Jan 1, 2021
320.96 M CNY
Jan 1, 2022
261.89 M CNY
Jan 1, 2023
299.02 M CNY
Jan 1, 2024
285.19 M CNY
Jan 1, 2025
313.63 M CNY
The Vcanbio Cell & Gene Engineering Corp Operating Cash Flow history
YEAROperating Cash FlowYoY
313.63 MCNY+9.97%
285.19 MCNY-4.62%
299.02 MCNY+14.18%
261.89 MCNY-18.40%
320.96 MCNY+31.35%
244.35 MCNY+1.19%
241.49 MCNY+85.64%
130.08 MCNY+85.12%
70.27 MCNY-51.09%
143.67 MCNY+1,657.41%
8.17 MCNY-96.31%
221.45 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp Ltd is a biotechnology company based in Tianjin, China, operating within the healthcare sector. The company has been publicly traded since its IPO on May 4, 1993, and is listed under the ticker 600645.SS with ISIN CNE000000545. It employs 2,332 full-time staff and focuses on the development of life sciences technology. Vcanbio engages in cell culture, gene detection, and storage services, as well as the production and sale of cytokines culture solutions, cosmetics, and detection reagents. The company primarily serves domestic markets in China, with its headquarters located in Tianjin. Its website is http://www.vcanbio.com. The firm's business activities include the development and application of biotechnology solutions, though specific details on product names, acquisitions, or additional financial figures are not provided in the available information. Vcanbio operates as a public company with a presence in the Chinese biotechnology industry, emphasizing innovation in cell and gene engineering. Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

Operating Cash Flow of Vcanbio Cell & Gene Engineering Corp is 313.63 M CNY in 2025.

Operating Cash Flow of Vcanbio Cell & Gene Engineering Corp changed from 285.19 M CNY to 313.63 M CNY, representing a 9.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Vcanbio Cell & Gene Engineering Corp historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Vcanbio Cell & Gene Engineering Corp

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Vcanbio Cell & Gene Engineering Corp